Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polyarteritis nodosa revisited.

Inés Colmegna1, José A Maldonado-Cocco

  • 1LSU Medical Center, 1542 Tulane Ave., New Orleans, LA 70112, USA. inescolmegna@yahoo.com

Current Rheumatology Reports
|July 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Umbilical cord mesenchymal stromal cells for respiratory complications of COVID-19 infection (ProTrans): phase II randomized clinical trial.

Cytotherapy·2026
Same author

Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.

Rheumatology and therapy·2025
Same author

A novel high-dimensional model for identifying regional DNA methylation QTLs.

Biostatistics (Oxford, England)·2025
Same author

Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 1: Preexisting Inflammatory Arthritides.

The Journal of rheumatology·2025
Same author

Understanding Patient and Physician Perspectives Regarding Innovative Research in Rheumatoid Arthritis.

The Journal of rheumatology·2025
Same author

Canadian Rheumatology Association/Canadian Research Group of Rheumatology in Immuno-Oncology Living Guidelines for Baseline Immunosuppression in Individuals With Preexisting Rheumatic Diseases Initiating Immune Checkpoint Inhibitors. Part 2: Preexisting Systemic Autoimmune Rheumatic Diseases.

The Journal of rheumatology·2025

Polyarteritis nodosa (PAN) is a rare vasculitis affecting medium or small arteries. Treatment differs based on cause, with corticosteroids and cyclophosphamide for idiopathic PAN, and plasmapheresis/antivirals for hepatitis B-related PAN.

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Polyarteritis nodosa (PAN) is a rare systemic vasculitis.
  • Characterized by necrotizing inflammation of medium-sized or small arteries.
  • Affects nearly all organs except lungs, manifesting as peripheral neuropathy, osteoarticular, renal, and gastrointestinal issues.

Purpose of the Study:

  • To differentiate between limited vs. systemic and idiopathic vs. hepatitis B-related PAN.
  • To highlight differences in pathogenetic mechanisms, treatment, and prognosis.
  • To inform clinical management strategies for PAN.

Main Methods:

  • Review of existing literature on Polyarteritis Nodosa.
  • Analysis of diagnostic criteria and clinical manifestations.

Related Experiment Videos

  • Comparison of treatment protocols for different PAN subtypes.

    • Main Results:

    • Idiopathic PAN treatment: Corticosteroids plus cyclophosphamide is standard, especially for severe cases.
    • Hepatitis B-related PAN treatment: Plasmapheresis and antiviral agents are key.
    • Distinguishing PAN subtypes is crucial for effective management and improved outcomes.

    Conclusions:

    • Effective management of Polyarteritis Nodosa requires distinguishing between idiopathic and hepatitis B-related forms.
    • Tailored treatment strategies, including immunosuppressants or antiviral therapies, are essential.
    • Further research into pathogenetic mechanisms can refine therapeutic approaches.